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Objectives The aim of this study was to evaluate the effect of statins in decreasing cardiovascular events in
women and men.
Background Published data reviews have suggested that statins might not be as effective in women as in men in decreasing
cardiovascular events.
Methods Published data searches and contacts with investigators identified 18 randomized clinical trials of statins with
sex-specific outcomes (N  141,235, 40,275 women, 21,468 cardiovascular events). Odds ratios (ORs) and
95% confidence intervals (CIs) for cardiovascular events were calculated for women and men separately with
random effects meta-analyses.
Results The cardiovascular event rate was lower among those randomized to statin intervention than in those random-
ized to control (low-dose statin in 4 studies, placebo in 11 studies, usual care in 3 studies) and similar in women
and men (OR: 0.81, 95% CI: 0.75 to 0.89; p  0.0001, and OR: 0.77, 95% CI: 0.71 to 0.83, p  0.0001, respec-
tively). The benefit of statins was statistically significant in both sexes, regardless of the type of control, baseline
risk, or type of endpoint and in both primary and secondary prevention. All-cause mortality was also lower with
statin therapy both in women and men without significant interaction by sex (p for interaction  0.4457).
Conclusions Statin therapy is associated with significant decreases in cardiovascular events and in all-cause mortality in
women and men. Statin therapy should be used in appropriate patients without regard to sex. (J Am Coll
Cardiol 2012;59:572–82) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.067Randomized controlled clinical trials and meta-analyses
have shown a benefit of statins in decreasing morbid and
mortal cardiovascular events in apparently healthy individ-
uals and in those with clinically evident cardiovascular
disease (CVD) (1–6). However, there is insufficient infor-
mation on the benefits of statins in women especially in
primary prevention (7–9). Reviews and meta-analyses have
shown improved outcomes with statins in both women and
men without significant interaction by sex (10–11). How-
ever, they did not show statistically significant effects in
women. This could be related to under-representation of
women in trials and underscores the need to explore
sex-related differences that would provide a basis for clinical
strategies to improve outcomes for women (12–15).
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Methods
Study selection. The meta-analysis was performed accord-
ing to the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses statement (16). With Medline, the
Cochrane Library, the Central Register of Controlled Tri-
als, Web of Science, and ClinicalTrials.gov, we performed a
systematic published data search of randomized clinical
trials of statin therapy where sex-specific data were pre-
sented through June 30, 2010. Trials were eligible for
inclusion in the meta-analysis if they were controlled,
randomized, and investigator- and patient-blind and if they
presented data by sex. We sought to obtain missing mor-
tality data by contacting the investigators of all studies
where sex-specific all-cause mortality data were not pub-
lished. Studies with fewer than 100 patients or fewer than 5
deaths/randomized group were excluded. With the search
strategy described in Online Table 1, we identified 2,332
potentially appropriate titles for possible inclusion in the
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ated by 2 investigators (W.J.K., J.B.K.) for possible
inclusion in the study. Eighteen trials fulfilled all criteria
for inclusion in the meta-analysis. The studies were
evaluated with regard to the similarity of baseline char-
acteristics, having defined eligibility criteria, blinding,
use of placebo or other control, intention-to-treat anal-
ysis, information on adherence, and the percentage lost to
follow-up (Online Table 2) (17).
Data extraction and quality assessment. The 18 studies
that fulfilled the inclusion criteria were categorized as
primary prevention (5) (Online References e22–
24,e26,e31,e33,e34) or secondary prevention, (6) (Online
eferences e21,e25,e27–e30,e32,e35,e36) as designed by
he investigators. All studies except 1 were funded by the
harmaceutical industry (Online Reference e30). In the
ajority of the studies, an independent data center was
esponsible for the data and analysis. The approximate
elative potency of the statin used (1 for lovastatin and
ravastatin, 2 for simvastatin, 4 for atorvastatin, and 8 for
osuvastatin) and the relative dose used (calculated as the
roduct of the dose and the relative potency) were
abulated. A measure of the use of active therapy in the
ntervention and control groups (active medication dif-
erence [AMD]) was defined as the percentage of pa-
ients who actually received active therapy among those
andomized to receive it, minus the percentage of those who
ctually took active therapy among those who were random-
Figure 1 Published Data Search and Selection of Studies Inclu
Flow diagram of identification of published records retrieved from published data s
(i.e., reading of reviews and prior meta-analyses). Reasons for exclusion of potentized to control. The number of
randomized patients, the number
of primary endpoints, and the
number of deaths in the interven-
tion and control groups were re-
corded. The difference in the de-
crease of serum low-density
lipoprotein cholesterol (LDL-c)
concentration between the inter-
vention and control groups was
tabulated for each study. There
were no assumptions or modifica-
tions made concerning the data included in the analyses.
Sex-specific data on the number of randomized patients, the
number of primary endpoints, and the number of deaths in the
intervention and control groups were recorded.
Data synthesis and analysis. Pre-defined outcomes were
all-cause mortality and the primary endpoint as defined by
the investigators of each study. The rates of occurrence of
the primary endpoint and all-cause mortality (where avail-
able) in the intervention and control groups were calculated
for each study as a whole as well as by sex. Statistical
analyses were performed with JMP (version 7.0, SAS
Institute, Cary, North Carolina), Comprehensive Meta-
Analysis (version 2.2, Biostat, Englewood, New Jersey), and
R software (R Project for Statistical Computing). Odds
ratios (ORs) and 95% confidence intervals (CIs) were
calculated for each endpoint. Weighted pooled treatment
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CVD  cardiovascular
disease
LDL-c  low-density
lipoprotein cholesterol
OR  odds ratio
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Meta-Analysis of Statin Effects in Women Versus Men February 7, 2012:572–82effects were calculated for each study as a whole and by sex
with random effects models. In addition, analyses were
done separately for primary and secondary prevention
trials, by level of baseline risk and by type of endpoint.
Heterogeneity of the effects was evaluated with the Q
statistic. Sensitivity analysis was performed by repeating
the analysis 18 times, removing 1 study at a time. Also,
analyses were performed by classifying the trials into 3
groups: primary prevention (5) (Online References
e22,e33), secondary prevention (6) (Online References
e21,e25,e27– e30,e32,e35,e36), and “mixed”, which in-
cluded 5 studies where a significant proportion of pa-
tients might have had CVD (Online References
DescriptorsTable 1 Descriptors
Study
Primary Versus
Secondary Drug Dose
Statin
Dose
Relative
Potency
R
4S Secondary Simvastatin 27.0 27.0 2
AF-TEXCAPS Primary Lovastatin 30.0 30.0 1
ALLHAT-LLT Primary Pravastatin 40.0 40.0 1
ASCOT-LLA Primary Atorvastatin 10.0 10.0 4
AURORA Primary Rosuvastatin 10.0 10.0 8
CARE Secondary Pravastatin 40.0 40.0 1
CORONA Secondary Rosuvastatin 10.0 10.0 8
GISSI-P Secondary Pravastatin 20.0 20.0 1
GREACE Secondary Atorvastatin 24.0 24.0 4
HPS Primary Simvastatin 40.0 40.0 2
JUPITER Primary Rosuvastatin 20.0 20.0 8
LIPID Secondary Pravastatin 40.0 40.0 1
MEGA Primary Pravastatin 8.3 8.3 1
A to Z Secondary Simvastatin 80.0 80.0 2
PROSPER Primary Pravastatin 40.0 40.0 1
PROVE-IT Secondary Atorvastatin 80.0 80.0 4
TNT Secondary Atorvastatin 80.0 80.0 4
SEARCH Secondary Simvastatin 80.0 80.0 2
Active
Adherence
Control
Adherence
Active in
Control AMD
4S 90.0% 87.0 13.0 77.0
AF-TEXCAPS 71.0 63.0 37.0 34.0
ALLHAT-LLT 80.0 83.0 17.0 63.0
ASCOT-LLA 87.0 91.0 9.0 78.0
AURORA 91.7 89.5 10.5 81.2
CARE 96.0 92.0 8.0 88.0
CORONA 97.3 95.2 4.8 92.5
GISSI-P 86.2 81.2 18.8 67.4
GREACE 98.8 74.0 26.0 72.8
HPS 85.0 83.0 17.0 68.0
JUPITER 75.0 75.0 25.0 50.0
LIPID 89.0 91.0 9.0 80.0
MEGA 90.0 75.0 25.0 65.0
A to Z 66.0 68.0 32.0 34.0
PROSPER 86.0 86.0 14.0 72.0
PROVE-IT 67.0 69.6 30.4 36.6
TNT 92.8 94.7 5.3 87.5
SEARCH 90.0 93.0 7.0 83.0e23,e24,e26,e31,e34). Publication bias was examined byperforming cumulative meta-analysis, by the Duval and
Tweedie’s Trim and Fill method (18) and the fail-safe N
models of Rosenthal (19) and Orwin (20). The types of
these analyses were pre-specified. In addition, analyses
were performed by classifying the studies according to
annual risk for mortality derived by dividing the observed
absolute risk by the duration of the study in years.
Meta-analysis was performed by analyzing separately and
comparing the 9 studies with the higher annual risk with
the 9 studies with the lower annual risk as well as by
classifying the studies into high annual risk (2 or higher
[6] [Online References e23,e25,e26,e28,e31,e34]), me-
dium (above 1 but lower than 2 [5] [Online References
e
Control
Relative Dose
Control
Relative Dose Difference
(Act-Cntrl)
Follow-Up
(Months)
Placebo 0 54.0 67.0
Placebo 0 30.0 62.0
Usual Care 0 40.0 58.0
Placebo 0 40.0 40.0
Placebo 0 80.0 38.0
Placebo 0 40.0 60.0
Placebo 0 80.0 32.8
Usual Care 0 20.0 23.0
Usual Care 0 96.0 36.0
Placebo 0 80.0 60.0
Placebo 0 160.0 22.8
Placebo 0 40.0 73.2
Placebo 0 8.3 63.6
20 Simvastatin 40 120.0 24.0
Placebo 0 40.0 38.4
40 Pravastatin 40 280.0 24.0
10 Atorvastatin 40 280.0 58.8
20 Simvastatin 40 120.0 80.4
% Men Average Age % DM % HTN
% Annual Risk
in Control
81 58 4.5 26.0 1.5
85 58 12.2 22.0 0.5
49 66 35.2 100.0 2.7
81 63 24.6 100.0 1.1
62 64 26.0 39.6 14.5
86 59 15.5 42.5 1.7
86 73 29.5 63.0 10.6
86 60 13.7 36.5 1.8
79 58 19.5 43.0 1.0
75 64 19.0 41.0 2.6
62 66 0.0 56.7 1.2
83 62 9.0 41.5 1.8
31 58 21.0 42.0 0.3
76 61 23.5 50.0 2.3
48 75 11.8 61.9 3.2
79 58 17.6 50.0 1.1
81 61 15.0 54.3 1.2
83 64 11.0 42.0 2.4
Continued on next pageelativ
Dose
54.0
30.0
40.0
40.0
80.0
40.0
80.0
20.0
96.0
80.0
160.0
40.0
8.3
160.0
40.0
320.0
320.0
160.0
AMR
6.92
1.92
4.71
9.67
8.73
12.00
20.27
4.59
3.80
5.00
3.00
9.89
3.60
2.06
6.14
2.20
17.51
12.86e21,e24,e27,e29,e32,e35,e36]), and low risk (up to 1
Aocyste
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February 7, 2012:572–82 Meta-Analysis of Statin Effects in Women Versus Men[Online References e22,e30,e33]) (21). Also, we per-
formed meta-analysis including the 3 studies (5,14)
[Online Reference e33) that reported specific outcomes
(stroke, coronary heart disease [CHD] event). We exam-
ined, in addition to meta-analysis, effect of sex on
outcomes with meta-regression. A more detailed descrip-
ContinuedTable 1 Continued
Study % Prior CVD % Current Smokers % ASA
LDL Drop
Difference,
mg/dl
%
D
4S 100 25.5 37 68
AF-TEXCAPS 0 13 17 43
ALLHAT-LLT 14 23 31 23
ASCOT-LLA 19 33 17 43
AURORA 40 15 42 40
CARE 100 21 83 38
CORONA 100 9 60 63
GISSI-P 100 14 50 17
GREACE 100 5 88 33
HPS 87 14 63 39
JUPITER 0 16 17 54
LIPID 100 63 83 18
MEGA 0 21 39 21
A to Z 100 41 98 15
PROSPER 44 27 36 50
PROVE-IT 100 37 100 33
TNT 100 13 88 23
SEARCH 100 30 90 15
4S Death
AF-TEXCAPS Fatal MI, nonfatal MI, UA, sudden
ALLHAT-LLT Death
ASCOT-LLA Nonfatal MI, silent MI, fatal CHD
AURORA CVD death, nonfatal MI, nonfatal
CARE Major coronary event (CHD death
CORONA CVD death, nonfatal MI, nonfatal
GISSI-P Death, nonfatal MI, nonfatal stro
GREACE Death, nonfatal MI, UA, PCI/CAB
HPS Death, nonfatal MI, nonfatal stro
JUPITER MI, stroke, revascularization, hos
LIPID CHD death, nonfatal MI
MEGA First occurrence of CHD
A to Z CV death, nonfatal MI, readmissi
PROSPER CHD death, nonfatal MI, fatal stro
PROVE-IT Death, MI, hospitalized UA, revas
TNT CHD death, nonfatal MI, resuscita
SEARCH CHD death, MI, stroke, revascula
4S  Scandinavian Simvastatin Survival Study; ACS  acute coronary syndromes; Act  A
ntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; AMD  active
acetylsalicylic acid; ASCOT-LLA  Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering
on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events; Avg average
 cerebrovascular; CHD  coronary heart disease; CHF  congestive heart failure; Cntrl  Co
CVD  cardiovascular disease; Diff  difference; DM  diabetes mellitus; GISSI-P  Gruppo
Atorvastatin and Coronary Heart Disease Evaluation; HDL  high-density lipoprotein; HF  hea
Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin; LDL  low-den
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; MI 
Pravastatin in the Elderly at Risk; PROVE-IT  Pravastatin or Atorvastatin Evaluation and Infe
disease; SEARCH  Study of the Effectiveness of Additional Reductions in Cholesterol and Hom
angina.tion of the methods is included in the online appendix.Results
Description of studies. Table 1 includes data on the 18
studies included in the meta-analysis. The statin used in the
intervention group was atorvastatin in 4 trials (Online
References e24,e30,e35,e36), lovastatin in 1 (Online Refer-
rop
ce Inclusion Criteria Ref. #
CHD; angina and/or MI e21
Average TC and LDL below-average HDL e22
Htn; LDL 120–189 mg/dl (100–129 mg/dl for CHD; 15% CHD) e23
Htn; TC 250 mg/dl e24
Hemodialysis e26
AMI; TC 240 mg/dl e27
NYC functional class II–IV ischemic systolic HF e28
AMI e29
CHD e30
CHD or PVD or cerebrovascular disease or DM e31
LDL 130 mg/dl and age (50 yrs for men, 60 yrs for women) 5
MI or UA e32
TC 220–270 mg/dl e33
ACS; TC 250 mg/dl e25
CVD or (smoker, HTN, or DM) and TC 155–348 mg/dl e34
ACS e35
CHD and LDL 130 mg/dl e36
MI 6
Primary Endpoint
ac death
tal MI, CABG, PTCA)
, stroke
onary or noncoronary revascularization
d UA, CVD death
ACS, stroke
nfatal stroke
ation
rdiac arrest, fatal or nonfatal stroke, HF hospitalization, peripheral arterial disease
AF-TEXCAPS  Air Force/Texas Coronary Atherosclerosis Prevention Study; ALLHAT-LLT 
tion difference; AMI  acute myocardial infarction; AMR  active medication ratio; ASA 
to Z  Aggrastat to Zocor; AURORA  A Study to Evaluate the Use of Rosuvastatin in Subjects
 coronary artery bypass graft surgery; CARE Cholesterol and Recurrent Events; Cerebrovasc
ORONA  Controlled Rosuvastatin Multinational Study in Heart Failure; CV  cardiovascular;
o per lo Studio della Sopravvivenza nell’lnfarto miocardico – Prevenzione; GREACE  Greek
re; HPS  Heart Protection Study; HTN  hypertension; JUPITER  Justification for the Use of
oprotein; LIPID  Long-Term Intervention with Pravastatin in Ischaemic Disease; MEGA 
rdial infarction; PCI  percutaneous coronary intervention; PROSPER  Prospective Study of
herapy; PTCA  percutaneous transluminal coronary angioplasty; PVD  peripheral vascular
ine; Smoke  smoker; TC  total cholesterol; TNT  Treating to New Targets; UA  unstableLDL D
ifferen
36.2
28.7
15.8
32.3
40.2
27.3
46.2
11.2
20.7
29.8
50.0
9.0
13.4
13.5
34.0
31.1
26.3
15.2
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Meta-Analysis of Statin Effects in Women Versus Men February 7, 2012:572–82e32–e34), rosuvastatin in 3 (5) (Online References e26,e28),
and simvastatin in 4 (6) (Online References e21,e25,e31).
Eight trials were designed as primary prevention trials (5)
(Online References e22–e24,e26,e31,e33,e34), and 10 were
designed as secondary prevention trials (6) (Online Refer-
ences e21,e25,e27–e30,e32,e35,e36). Five of the primary
prevention studies included a proportion of patients with
CVD (Online References e23,e24,e26,e31,e34). These
studies were defined as “mixed” in the sensitivity analysis.
Data on all-cause mortality were not available for 5 studies
(6) (Online References e24–e26,e28). Overall, the meta-
analysis included 141,235 patients, 21,468 primary events,
and 13,710 deaths (3,898 deaths in studies with sex-specific
mortality data). Different studies used study-specific defini-
tions of primary events (Table 1) and had different durations
of follow-up (47.9  18.9 months). The mean relative dose
in the intervention group was 98.2  93.5 mg. The mean
ifference in relative statin dose between the intervention
nd the control groups was 89.4  79.8 mg. Mean
ollow-up was 48  19 months. On average, 85.5  9.9%
of those randomized to active therapy actually received it
compared with 17.2  9.9% of those randomized to the
control group. On average, 72.9  15.9% of the patients in
he clinical trials were men. The mean age was 62.7  5.1
ears. Seventeen percent (17.1  8.8%) of the patients had
iabetes, 51.3  21.3% had hypertension, 23.3  13.9%
ere current smokers, 57.6  29.5% were taking aspirin,
nd 66.9  42.8% had prior CVD (ranging from 0% in 3
rials to 100% in 10 trials). The difference in LDL-c
owering (compared with baseline) between the intervention
nd control groups was 35.3 16.3 mg/dl. When expressed
s a percentage of the LDL-c at baseline, this difference was
6.7  12% (Table 1).
rimary events in women and men. A statistically signif-
cant decrease in the primary endpoint was observed in
omen (OR: 0.81, 95% CI: 0.75 to 0.89, p  0.0001) as
ell as in men (OR: 0.77, 95% CI: 0.71 to 0.83, p 
.0001), with similar lowering in both sexes (p for interac-
ion  0.1837) (Table 2, Online Fig. 1). In women, the
enefit with respect to the primary event seemed more
ronounced in secondary prevention trials than in primary
revention trials (OR: 0.78, 95% CI: 0.70 to 0.88, p 
.0001, and OR: 0.85, 95% CI: 0.75 to 0.98, p  0.0209,
espectively, p for interaction  0.3397) (Online Fig. 2).
lso, the benefit of the statin intervention was similar in
tudies where placebo/usual care or low-dose statin were
sed in the control group (OR: 0.81, 95% CI: 0.72 to 0.91,
 0.0005 for both types of studies, p for interaction 
.4545) (Online Fig. 3).
Sensitivity analysis of the primary event in women was
erformed 18 times with the leave-one-out method, result-
ng in ORs ranging from 0.80 (95% CI: 0.73 to 0.88, p 
.0001) to 0.83 (95% CI: 0.77 to 0.90, p  0.0001).
ublication bias was assessed by performing cumulative
eta-analysis with trials ordered by increasing weight andy funnel plot analysis. With cumulative meta-analysis, the vssociated funnel plot, and the Duval and Tweedie’s Trim
nd Fill method, the effects of statins in lowering the
rimary endpoint remained statistically significant (OR:
.84, 95% CI: 0.76 to 0.93, p  0.035), by including 3
mputed trials (18). Rosenthal’s fail-safe N indicated that
52 missing negative studies would be needed to bring the
value of the effect to 0.05 (19). Orwin’s fail-safe N
eeded to bring the OR to 0.95 was 50 (20).
The primary endpoint was also lower in men when all
tudies were examined (OR: 0.77, 95% CI: 0.72 to 0.84,
 0.0001) and when primary prevention trials were
nalyzed separately from secondary prevention trials (OR:
.73, 95% CI: 0.63 to 0.84, p  0.0001 for primary
revention, and OR: 0.79, 95% CI: 0.72 to 0.87, p 
.0001 for secondary prevention, p for interaction by type of
revention 0.2122) (Online Fig. 4). Meta-analysis by level
f risk indicated a statistically significant benefit of statin
herapy at all levels of risk in both women (OR: 0.88, 95%
I: 0.81 to 0.95, p  0.0014 for high risk, OR: 0.75, 95%
I: 0.64 to 0.89, p  0.0011 for medium risk, and OR:
.59, 95% CI: 0.41 to 0.87, p  0.0066 for low risk) and
en (OR: 0.87, 95% CI: 0.77 to 0.98, p  0.0254 for high
isk, OR: 0.73, 95% CI: 0.67 to 0.80, p  0.0001 for
edium risk, and OR: 0.61, 95% CI: 0.41 to 0.92, p 
.0170 for low risk) for the primary event (Figs. 2 and 3).
his more-pronounced benefit in groups at low risk was also
bserved by meta-regression. Thus, meta-regression showed
statistically significant relationship of annual risk of
ortality of each trial to the OR for the primary endpoint
n both women (slope of log(OR): 0.01819, 95% CI:
.00017 to 0.03620, p  0.04783) and men (slope of
og(OR): 0.01925, 95% CI: 0.00819 to 0.03032, p 
.00065), indicating a greater benefit (lower OR) in low-
isk groups. A statistically significant benefit with respect to
troke was observed in the meta-analysis of the 3 studies
ith sex-specific outcomes (OR: 0.74, 95% CI: 0.55 to 0.99,
 0.0396 for women, and OR: 0.70, 95% CI: 0.57 to
.84, p  0.0002 for men). The benefit for CHD was also
tatistically significant (OR: 0.78, 95% CI: 0.67 to 0.94, p
.0090 for women, and OR: 0.73, 95% CI: 0.66 to 0.81,
 0.0001) (Fig. 4). In the 2 studies with sex-specific
eports on adverse effects, there was no significant difference
etween women and men (JUPITER [Justification for the
se of Statins in Prevention: An Intervention Trial Evalu-
ting Rosuvastatin], TNT [Treating to New Targets]). In
he TNT trial women were slightly more likely to report
yalgia in both active and control treatment groups, and
here was no difference between treatment groups for
omen and men.
Meta-regression showed a statistically significant rela-
ionship between the benefit of statin therapy and the
ifference in LDL-c lowering between intervention and
ontrol groups (slope log(OR) vs. LDL:0.00416, 95% CI:
0.00642 to 0.00910, p  0.0003) (Online Fig. 5).
Pairwise comparisons of the primary event for womenersus men did not show a significant difference between
577JACC Vol. 59, No. 6, 2012 Kostis et al.
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SD  0.062, p  0.68) in multivariate meta-regression.
This corresponds to an OR ratio (ORmen/ORwomen) of
0.77  0.54, a nonsignificant trend for men to benefit more
from statins. Also, a significant difference in all-cause
mortality was not observed (log(OR): difference  0.002,
SD  0.215, p  0.993, indicating a nearly identical effect
of statins in women and men, OR: 0.998).
To examine whether differences in primary events in
women versus men were influenced by trial characteristics,
we performed multivariate meta-regression analyses. They
showed a trend implying that men might be more likely to
benefit from active therapy than women (Online Appendix).
All-cause mortality in men and women. All-cause mor-
Primary Events by SexTable 2 Primary Events by Sex
Study
Men Primary
Events Active
Men
Active (n)
Men Primary
Events Control
4S 155 1,814 231
AF-TEXCAPS 109 2,805 170
ALLHAT-LLT 406 2,659 398
ASCOT-LLA 81 4,189 137
AURORA 247 851 267
CARE 384 1,795 469
CORONA 554 1,921 577
GISSI-P 97 1,854 113
GREACE 50 624 101
HPS 1,666 7,727 2135
JUPITER 103 5,475 181
LIPID 622 3,756 777
MEGA 40 1,228 65
A to Z 239 1,716 272
PROSPER 222 1,396 279
PROVE-IT 376 1,634 424
TNT 1,113 4,054 1330
SEARCH 1,277 5,005 1325
Women Primary
Events Active
Women
Active (n)
Women Primary
Events Control
4S 27 407 25
AF-TEXCAPS 7 499 13
ALLHAT-LLT 260 2,511 277
ASCOT-LLA 19 979 17
AURORA 149 538 141
CARE 46 286 80
CORONA 138 593 155
GISSI-P 23 284 23
GREACE 13 176 27
HPS 367 2,542 450
JUPITER 39 3,426 70
LIPID 112 756 134
MEGA 26 2,638 36
A to Z 91 549 99
PROSPER 186 1,495 194
PROVE-IT 94 465 120
TNT 292 941 347
SEARCH 200 1,026 228
AR  absolute risk; RR  relative risk; other abbreviations as in Table 1.tality was lower in women when all studies were examined(OR: 0.90, 95% CI: 0.82 to 0.99, p  0.0344) (Table 3,
Online Fig. 6) as well as when primary prevention trials
were analyzed separately (OR: 0.87, 95% CI: 0.78 to 0.97,
p  0.0142, p for interaction  0.5122). The effect on
all-cause mortality in women was not statistically significant
for secondary prevention trials (OR: 1.03, 95% CI: 0.84 to
1.25, p  0.7926). All-cause mortality was also lower in
men when all studies were examined (OR: 0.84, 95% CI:
0.77 to 0.92, p  0.0003) (Online Fig. 6) as well as when
the secondary prevention trials were analyzed (OR: 0.76,
95% CI: 0.66 to 0.87, p  0.0001). In men, all-cause
mortality was not significantly lower in the intervention
group for primary prevention trials (OR: 0.92 95% CI:
0.84 to 1.01, p  0.0664). However, there was no
en
trol (n)
Men Primary
Event Active AR
Men Primary Event
Control AR
Men Primary
Event RR
,803 8.5 12.8 66.7
,803 3.9 6.1 64.1
,645 15.3 15.0 101.5
,174 1.9 3.3 58.9
872 29.0 30.6 94.8
,788 21.4 26.2 81.6
,910 28.8 30.2 95.5
,830 5.2 6.2 84.7
632 8.0 16.0 50.1
,727 21.6 27.6 78.0
,526 1.9 3.3 57.4
,742 16.6 20.8 79.8
,248 3.2 5.3 62.5
,680 13.9 16.2 86.0
,408 15.9 19.8 80.3
,617 23.0 26.2 87.8
,045 27.5 32.9 83.5
,007 25.5 26.5 96.4
en
l (n)
Women Primary
Event Active AR
Women Primary Event
Control AR
Women Primary
Event RR
20 6.6 6.0 111.4
98 1.4 2.6 53.7
40 10.4 10.9 94.4
63 1.9 1.8 109.9
12 27.7 27.5 100.6
90 16.1 27.6 58.3
87 23.3 26.4 88.1
03 8.1 7.6 106.7
68 7.4 16.1 46.0
40 14.4 17.7 81.5
75 1.1 2.1 54.9
60 14.8 17.6 84.0
18 1.0 1.3 74.4
52 16.6 17.9 92.4
05 12.4 12.9 96.5
46 20.2 26.9 75.1
61 31.0 36.1 85.9
26 19.5 22.2 87.7M
Con
1
2
2
4
1
1
1
7
5
3
1
1
1
1
4
5
Wom
Contro
4
4
2,5
9
5
2
5
3
1
2,5
3,3
7
2,7
5
1,5
4
9
1,0statistically significant interaction between the decrease
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interaction  0.2122).
Discussion
The findings of this study are consonant with a wealth of
information from randomized clinical trials and meta-
analyses. The Cholesterol Treatment Trialists’ Collabora-
tion individual participant data meta-analyses showed de-
creases in cardiovascular events and mortality with statin use
and that more intensive lowering of LDL-c produced
further reductions in cardiovascular events (1,22). Our
analysis, indicating a decrease in the primary endpoint and
all-cause mortality and a positive association between
LDL-c lowering and lower risk, is consistent with the
Cholesterol Treatment Trialists’ findings. In the present
study, the benefit of statins in reducing primary endpoints
was observed in women and men and in both primary and
secondary prevention without significant difference between
the 2 sexes. Lower all-cause mortality was also observed in
both women and men. Meta-regression with stepwise
variable selection suggested that the benefit was more
pronounced in men in studies with higher percentages of
smokers or patients with CVD and lower percentage on
aspirin. The mortality benefit was statistically significant for
Figure 2 Forest Plot for the Primary Event by Level of Risk of P
Solid squares represent the odds ratios in individual trials and have a size proportiona
95% confidence intervals (CIs) for individual trials and summary statistics. Pooled estiprimary prevention in women and for secondary preventionin men, although there was no significant interaction by sex
in these analyses.
Studies classified as primary prevention frequently
include patients with CVD, and the distinction between
primary and secondary prevention is ambiguous (21,23).
For this reason, we performed analyses by risk level. They
indicate a benefit across risk levels in both women and
men, and meta-regression shows a relationship between
risk and the benefit of statins. The reasons for the more
pronounced benefit of statins in studies that enrolled
low-risk patients, both by meta-regression and by sub-
setting, are not known. Also, because the primary end-
point was different across studies, we analyzed the data
according to whether the endpoint included or did not
include stroke or angina, endpoints more likely to occur
in women. The analyses indicated a benefit was shown for
studies including either stroke or angina as a component
of the combined endpoint. A recent Cochrane report on
the use of statins for primary prevention agrees with our
finding of reduction of cardiovascular events but does not
include sex-specific results (21). The authors stated that
caution should be taken in prescribing statins for persons
at low cardiovascular risk (below 1% annual all-cause
mortality risk). We found a benefit in both women and
men in the 3 studies with annual risk 1% or below
ipants in Each Study in Women
e inverse of the variance. Horizontal lines, diamonds, and squares denote the
were computed from a random effects model. Trial acronyms as in Table 1.artic
l to th
mates(Online References e22,e30,e33). However, the costs and
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tion to the absolute benefit in decreasing events (24). The
estimated cost of preventing 1 cardiovascular event with
rosuvastatin in the JUPITER trial is $287,000 (21),
although with the decrease in the price of generic statins
the cost would be lower.
Significant differences between women and men were not
observed in the 2 studies reporting sex-specific adverse
events, and women are under-represented in clinical trials
(5,12,14,25). This underscores the importance of collecting
sex-specific data and of increasing the percentage of women
in clinical trials.
Although LDL-c is a strong predictor of CHD in both
women and men and similar treatment approaches are
recommended for both sexes, CHD might have different
manifestations in women, and medications might have
different effects in women than in men (7–10,12–15). For
example, aspirin seems to have differential effects in primary
prevention of CVD, with men deriving benefit primarily in
reduction of myocardial infarction and women in reduction
of ischemic stroke (26). The present study, however, does
not indicate any sex differences in the beneficial effects of
statins in either primary or secondary prevention.
Previous meta-analyses, most conducted before the publica-
tion of the JUPITER trial, have implied that some of the
benefits of statins do not pertain to women in primary
Figure 3 Forest Plot for the Primary Event by Level of Risk of P
Solid squares represent the odds ratios in individual trials and have a size proportiona
95% confidence intervals (CIs) for individual trials and summary statistics. Pooled estiprevention and that all-cause mortality is not decreased inwomen (7–10). Rosenberg and Allard (7) have stated that
safety meta-analyses do not disaggregate for women and do
not consider female vulnerability to statin-induced muscle
problems and women-centered concerns such as breast cancer,
miscarriage, and birth defects. Wenger et al. (13–15) has
emphasized that, as the population ages, the incidence of CVD
will increase among women and that the great majority of
persons over 80 years are women and are more likely to suffer
cardiovascular events. Thus, meta-analyses such as the present
study provide important information from a large proportion
of the population. Although statin therapy benefits both
women and men, lipid-lowering therapy with statin drugs is
currently underused. Barham et al. (27), examining a sample of
60 North Carolina primary care practices participating in a
randomized practice-based trial, did not find large differences
by sex in screening or appropriateness of management. Life-
style interventions are preferable in primary prevention but
they might be difficult to implement and to maintain (28).
Study limitations. Limitations of the study include possible
publication bias, although it is unlikely that this has a signifi-
cant sex-specific effect, because in all trials the hypothesis and
the primary endpoints analyzed were not sex-specific. Exclu-
sion of studies without sex-specific data diminishes the number
of studies available for the meta-analysis and the power of the
analyses. This study indicates that statin therapy is beneficial in
both women and men. The trend suggesting higher benefit in
ipants in Each Study in Men
e inverse of the variance. Horizontal lines, diamonds, and squares denote the
were computed from a random effects model. Trial acronyms as in Table 1.artic
l to th
matesmen than in women must be interpreted with caution, because
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of patient-level data that might be available will provide more
precise estimates than those presented in this report (1,22). It
is possible that such analyses, although showing benefits of
statin therapy in women, will reveal a more pronounced benefit
in men among certain subsets, because trends in that direction
were observed in this study. However, we should not over-
interpret the data of the 18 trials that represent, to our
knowledge, all available information at the time of this report.
Conclusions
Statins decrease cardiovascular events and all-cause mortality in
both women and men. The effect on cardiovascular events is
All-Cause Mortality by SexTable 3 All-Cause Mortality by Sex
Study
Men Deaths
Active
Men
Active (n)
Men Deaths
Control
4S 155 1,814 231
AF-TEXCAPS 69 2,805 70
ALLHAT-LLT 406 2,659 398
ASCOT-LLA — — —
AURORA — — —
CARE 159 1,795 173
CORONA — — —
GISSI-P 55 1,854 76
GREACE 19 624 32
HPS 1,102 7,727 1245
JUPITER 138 5,475 170
LIPID 424 3,756 555
MEGA 21 1,228 27
A to Z — — —
PROSPER 178 1,396 171
PROVE-IT 34 1,634 52
TNT 226 4,054 237
SEARCH — — —
Women Deaths
Active
Women
Active (n)
Women Deaths
Control
4S 27 407 25
AF-TEXCAPS 11 499 7
ALLHAT-LLT 260 2,511 277
ASCOT-LLA — — —
AURORA — — —
CARE 21 286 23
CORONA — — —
GISSI-P 17 284 12
GREACE 4 176 8
HPS 226 2,542 262
JUPITER 60 3,426 77
LIPID 74 756 78
MEGA 22 2,638 39
A to Z — — —
PROSPER 120 1,495 135
PROVE-IT 12 465 14
TNT 58 941 45
SEARCH — — —
Abbreviations as in Tables 2 and 3.present in both primary and secondary prevention trials.Therefore, statin therapy should be used in appropriate pa-
tients without regard to sex. It seems that, with respect to statin
therapy, what is good for the gander is good for the goose (29).
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